Abstract | OBJECTIVE: STUDY DESIGN: Twenty-two SOKCs, 22 primary NSOKCs, and eight recurrent NSOKCs were evaluated by immunohistochemistry using anti-RANKL and anti-OPG antibodies. The angiogenic index was determined by microvessel count (MVC) using anti-CD34 antibody. Anti-α-smooth muscle actin (α-SMA) antibody was used for the identification of myofibroblasts. RESULTS: Analysis of the expression of RANKL and OPG in the epithelial lining and fibrous capsule did not reveal significant differences between groups (P>0.05). In the epithelial lining, the RANKL/OPG ratio was RANKL<OPG and RANKL=OPG in most primary NSOCKs (54.5%) and SOKCs (59.1%), respectively (P>0.05). In the fibrous capsule, the ratio was RANKL=OPG in most primary (81.8%) and recurrent NSOKCs (75.0%) and in most SOKCs (45.5%) (P>0.05). No significant differences in the angiogenic index or number of myofibroblasts were observed between primary NSOKCs, recurrent NSOKCs, and SOKCs (P>0.05). CONCLUSIONS: The present results suggest that differences in the biological behaviour of SOKCs and NSOKCs may not be related to the expression of RANKL and OPG, to the RANKL/OPG ratio, to the angiogenic index, or to the number of myofibroblasts in these lesions.
|
Authors | Cassiano Francisco Weege Nonaka, Roberta Barroso Cavalcante, Renato Luiz Maia Nogueira, Lélia Batista de Souza, Leão Pereira Pinto |
Journal | Archives of oral biology
(Arch Oral Biol)
Vol. 57
Issue 3
Pg. 230-7
(Mar 2012)
ISSN: 1879-1506 [Electronic] England |
PMID | 21871606
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antigens, CD34
- Osteoprotegerin
- RANK Ligand
|
Topics |
- Antigens, CD34
(analysis)
- Basal Cell Nevus Syndrome
(metabolism)
- Bone Resorption
(metabolism)
- Epithelial Cells
(metabolism)
- Humans
- Immunohistochemistry
- Myofibroblasts
(metabolism)
- Neovascularization, Pathologic
- Odontogenic Cysts
(blood supply, metabolism)
- Osteoprotegerin
(metabolism)
- RANK Ligand
(metabolism)
|